Patients will be recruited who have peripheral neuropathy due to chemotherapy. They will be
given a blinded treatment of gel containing either menthol (3%) or placebo to be applied for
6 weeks, twice a day. Assessments of pain, neuropathic symptoms and impact on quality of life
will be done at baseline, 6 weeks and 12 weeks. Functional magnetic resonance imaging (fMRI)
scans will be done at baseline and 6 weeks. Physical activity data will also be collected to
be analysed in conjunction with pain assessments.